Dr. Graubert received his undergraduate degree from Dartmouth College and his MD from Harvard Medical School and then completed an internship and residency in Internal Medicine at Yale-New Haven Hospital. He was a research associate at Yale before moving to Washington University in St. Louis where he was a Hematology/Oncology fellow and post-doctoral research associate with Tim Ley. He joined the Washington University faculty and started his laboratory in 1998. Since 2013, Dr. Graubert has led the Hematologic Malignancy Program at the Massachusetts General Hospital Cancer Center and holds the Jon and JoAnn Hagler Chair in Oncology. Dr. Graubert is a Professor of Medicine at Harvard Medical School and co-leads the Leukemia Program for the Dana-Farber/Harvard Cancer Consortium.

Dr. Graubert has led a research group for more than 25 years that is focused on the molecular pathogenesis of MDS and other myeloid malignancies. With colleagues at Washington University, he performed the first whole genome sequencing studies in MDS and identified mutations in U2AF1, helping to open a new line of investigation into the role of RNA splicing gene mutations in the biology of MDS. His group subsequently showed that RNA splicing mutations create a vulnerability in the DNA damage response that could be exploited as a new therapy for MDS.

Dr. Graubert will continue the rich legacy established by Dr. Lewis of funding innovative research through the Developmental Research Grant program and supporting promising new investigators through the Young Investigator Award mechanism, in addition to new initiatives that will be announced in the coming months. Dr. Graubert is delighted that Scott Hiebert, PhD will continue in his role as Chair of the Scientific Advisory Board.